CoChat

The vaginal microbiome as a predictor for outcome of in vitro fertilization with or without intracytoplasmic sperm injection: a prospective study

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

STUDY QUESTION: Is the presence or absence of certain vaginal bacteria associated with failure or success to become pregnant after an in vitro fertilization (IVF) or IVF with intracytoplasmic sperm injection (IVF-ICSI) treatment? SUMMARY ANSWER: Microbiome profiling with the use of interspace profiling (IS-pro) technique enables stratification of the chance of becoming pregnant prior to the start of an IVF or IVF-ICSI treatment. WHAT IS KNOWN ALREADY: Live-birth rates for an IVF or IVF-ICSI treatment vary between 25 and 35% per cycle and it is difficult to predict who will or will not get pregnant after embryo transfer (ET). Recently, it was suggested that the composition of the vaginal microbiota prior to treatment might predict pregnancy outcome. Analysis of the vaginal microbiome prior to treatment might, therefore, offer an opportunity to improve the success rate of IVF or IVF-ICSI. STUDY DESIGN, SIZE, DURATION: In a prospective cohort study, 303 women (age, 20–42 years) undergoing IVF or IVF-ICSI treatment in the Netherlands were included between June 2015 and March 2016. PARTICIPANTS/MATERIALS, SETTING, METHODS: Study subjects provided a vaginal sample before the start of the IVF or IVF-ICSI procedure. The vaginal microbiota composition was determined using the IS-pro technique. IS-pro is a eubacterial technique based on the detection and categorization of the length of the 16S–23S rRNA gene interspace region. Microbiome profiles were assigned to community state types based on the dominant bacterial species. The predictive accuracy of the microbiome profiles for IVF and IVF-ICSI outcome of fresh ET was evaluated by a combined prediction model based on a small number of bacterial species. From this cohort, a model was built to predict outcome of fertility treatment. This model was externally validated in a cohort of 50 women who were undergoing IVF or IVF-ICSI treatment between March 2018 and May 2018 in the Dutch division of the MVZ VivaNeo Kinderwunschzentrum Düsseldorf, Germany. MAIN RESULTS AND THE ROLE OF CHANCE: In total, the vaginal microbiota of 192 women who underwent a fresh ET could be analysed. Women with a low percentage of Lactobacillus in their vaginal sample were less likely to have a successful embryo implantation. The prediction model identified a subgroup of women (17.7%, n = 34) who had a low chance to become pregnant following fresh ET. This failure was correctly predicted in 32 out of 34 women based on the vaginal microbiota composition, resulting in a predictive accuracy of 94% (sensitivity, 26%; specificity, 97%). Additionally, the degree of dominance of Lactobacillus crispatus was an important factor in predicting pregnancy. Women who had a favourable profile as well as <60% L. crispatus had a high chance of pregnancy: more than half of these women (50 out of 95) became pregnant. In the external validation cohort, none of the women who had a negative prediction (low chance of pregnancy) became pregnant. LIMITATIONS, REASONS FOR CAUTION: Because our study uses a well-defined study population, the results will be limited to the IVF or IVF-ICSI population. Whether these results can be extrapolated to the general population trying to achieve pregnancy without ART cannot be determined from these data. WIDER IMPLICATIONS OF THE FINDINGS: Our results indicate that vaginal microbiome profiling using the IS-pro technique enables stratification of the chance of becoming pregnant prior to the start of an IVF or IVF-ICSI treatment. Knowledge of their vaginal microbiota may enable couples to make a more balanced decision regarding timing and continuation of their IVF or IVF-ICSI treatment cycles. STUDY FUNDING/COMPETING INTEREST(S): This study was financed by NGI Pre-Seed 2014–2016, RedMedTech Discovery Fund 2014–2017, STW Valorisation grant 1 2014–2015, STW Take-off early phase trajectory 2015–2016 and Eurostars VALBIOME grant (reference number: 8884). The employer of W.J.S.S.C. has in collaboration with ARTPred acquired a MIND subsidy to cover part of the costs of this collaboration project. The following grants are received but not used to finance this study: grants from Innovatie Prestatie Contract, MIT Haalbaarheid, other from Dutch R&D tax credit WBSO, RedMedTech Discovery Fund, (J.D.d.J.). Grants from Ferring (J.S.E.L., K.F., C.B.L. and J.M.J.S.S.), Merck Serono (K.F. and C.B.L.), Dutch Heart Foundation (J.S.E.L.), Metagenics Inc. (J.S.E.L.), GoodLife (K.F.), Guerbet (C.B.L.). R.K. is employed by ARTPred B.V. during her PhD at Erasmus Medical Centre (MC). S.A.M. has a 100% University appointment. I.S.P.H.M.S., S.A.M. and A.E.B. are co-owners of IS-Diagnostics Ltd. J.D.d.J. is co-owner of ARTPred B.V., from which he reports personal fees. P.H.M.S. reports non-financial support from ARTPred B.V. P.H.M.S., J.D.d.J. and A.E.B. have obtained patents `Microbial population analysis’ (9506109) and `Microbial population analysis’ (20170159108), both licenced to ARTPred B.V. J.D.d.J. and A.E.B. report patent applications `Method and kit for predicting the outcome of an assisted reproductive technology procedure’ (392EPP0) and patent `Method and kit for altering the outcome of an assisted reproductive technology procedure’ by ARTPred. W.J.S.S.C. received personal consultancy and educational fees from Goodlife Fertility B.V. J.S.E.L. reports personal consultancy fees from ARTPred B.V., Titus Health B.V., Danone, Euroscreen and Roche during the conduct of the study. J.S.E.L. and N.G.M.B. are co-applicants on an Erasmus MC patent (New method and kit for prediction success of in vitro fertilization) licenced to ARTPred B.V. F.J.M.B. reports personal fees from Advisory Board Ferring, Advisory Board Merck Serono, Advisory Board Gedeon Richter and personal fees from Educational activities for Ferring, outside the submitted work. K.F. reports personal fees from Ferring (commercial sponsor) and personal fees from GoodLife (commercial sponsor). C.B.L. received speakers’ fee from Ferring. J.M.J.S.S. reports personal fees and other from Merck Serono and personal fees from Ferring, unrelated to the submitted paper. The other authors declare that they have no competing interests. TRIAL REGISTRATION NUMBER: ISRCTN83157250. Registered 17 August 2018. Retrospectively registered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/humrep/dez065

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Heatmap of all clustered vaginal swab samples. Top section shows the clustering of all analysed microbiome profiles. The clusters that coincide with the five known CSTs are shown (I-V). The columns represent the profile per individual. The rows represent the found species and the length of the interspace region in units of nucleotides (nt). This can be clustered into three groups at phyla level: Bacteroidetes, FAFV and Proteobacteria .
Figure 1 Heatmap of all clustered vaginal swab samples. Top section shows the clustering of all analysed microbiome profiles. The clusters that coincide with the five known CSTs are shown (I-V). The columns represent the profile per individual. The rows represent the found species and the length of the interspace region in units of nucleotides (nt). This can be clustered into three groups at phyla level: Bacteroidetes, FAFV and Proteobacteria .CC-BY-NC · From the PDF
Figure 2 The CSTs and the accompanying pregnancy outcome. The composition of the vaginal microbiome per CST and the accompanying distribution of pregnancy results (not pregnant or pregnant) per CST.
Figure 2 The CSTs and the accompanying pregnancy outcome. The composition of the vaginal microbiome per CST and the accompanying distribution of pregnancy results (not pregnant or pregnant) per CST.CC-BY-NC · From the PDF
Figure 3 The role of L. crispatus and L. iners in predicting pregnancy outcome. Relative rates of L. crispatus versus L. iners for each patient. Each circle represents a patient, the colour of the dot shows pregnancy outcome (green, pregnant; red, not pregnant). A : Patients with an unfavourable profile (34 of 192 women) are depicted as black crosses, they are removed from the data set in figures B -D . B: Of the remaining 158 women, 63 have a relative abundance of L. crispatus ≥ 60%. The pregnancy rate in this group is 15/63 = 24%. C: Women with a relative abundance of L. iners ≥ 60% show a pregnancy rate of 19/38 = 50%. D: When taking into account L. crispatus abundance alone, the group of women with a L. crispatus abundance ≤ 60% have a pregnancy rate of 50/95 = 53%.
Figure 3 The role of L. crispatus and L. iners in predicting pregnancy outcome. Relative rates of L. crispatus versus L. iners for each patient. Each circle represents a patient, the colour of the dot shows pregnancy outcome (green, pregnant; red, not pregnant). A : Patients with an unfavourable profile (34 of 192 women) are depicted as black crosses, they are removed from the data set in figures B -D . B: Of the remaining 158 women, 63 have a relative abundance of L. crispatus ≥ 60%. The pregnancy rate in this group is 15/63 = 24%. C: Women with a relative abundance of L. iners ≥ 60% show a pregnancy rate of 19/38 = 50%. D: When taking into account L. crispatus abundance alone, the group of women with a L. crispatus abundance ≤ 60% have a pregnancy rate of 50/95 = 53%.CC-BY-NC · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 270

Metadata

Authors
Koedooder, R., Singer, M., Schoenmakers, S., Savelkoul, P. H. M., Morré, S. A., de Jonge, J. D., Poort, L., Cuypers, W. J. S. S., Beckers, N. G. M., Broekmans, F. J. M., Cohlen, B. J., den Hartog, J. E., Fleischer, K., Lambalk, C. B., Smeenk, J. M. J. S., Budding, A. E., & Laven, J. S. E.
Affiliations
  • Erasmus MC (NL)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Maastricht University Medical Centre (NL)
  • Maastricht University (NL)
  • ARTPred B.V., Kruisweg, NC Hoofddorp, The Netherlands
  • Amsterdam University Medical Centers (NL)
  • Dutch Division, MVZ VivaNeo Kinderwunschzentrum Düsseldorf GmbH, Völklinger Straße 4, Düsseldorf, Germany
  • VivaNeo Medisch Centrum Kinderwens, Simon Smitweg, GA Leiderdorp, The Netherlands
  • University Medical Center Utrecht (NL)
  • Isala (NL)
  • Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Maastricht Universitair Medisch Centrum+, P. Debyelaan, HX Maastricht, The Netherlands
  • Radboud University Medical Center (NL)
  • Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Sint Elisabeth Ziekenhuis, Hilvarenbeekseweg, GC Tilburg, The Netherlands
Corresponding author
Koedooder, R
Venue
Human Reproduction
Published
2019-05-23
Volume
34
Issue
6
Pages
1042-1054
ISSN
  • 0268-1161 (ISSN-L)
  • 1460-2350
OpenAlex
W2945955929
Cited by
257
References
29
Citations by year
2026: 35 · 2025: 43 · 2024: 24 · 2023: 44 · 2022: 47 · 2021: 39 · 2020: 20 · 2019: 4
FWCI
22.59
Type
journal article
Language
en
Open access
Locations
  • Human Reproduction (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • Pure Amsterdam UMC (acceptedVersion, cc-by)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion)
  • Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • Danone
  • Amsterdam University Medical Centers
  • Radboud Universiteit
  • Vrije Universiteit Amsterdam
  • Universiteit Maastricht
  • Gedeon Richter (2014-2016)
  • Stichting voor de Technische Wetenschappen
  • Eurostars
Topics
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
vaginal microbiota, in vitro fertilization, intracytoplasmic sperm injection, pregnancy outcome prediction, 16S-23S rRNA gene, community state types, Lactobacillus, bacterial species, embryo implantation, embryo transfer, infertility, prediction model, external validation, fresh embryo transfer, frozen embryo transfer, endometrial receptivity, endometrial receptivity array, endometrial receptivity profiling
MeSH terms
Clinical Decision-Making, Lactobacillus crispatus, Adult, Birth Rate, DNA, Bacterial, Embryo Transfer, Female, Germany, Humans, Infertility, Female, Netherlands, Predictive Value of Tests, Pregnancy, Prospective Studies, RNA, Ribosomal, 16S, Time Factors, Vagina, Models, Statistical, Treatment Outcome, Risk Assessment, Sperm Injections, Intracytoplasmic, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The vaginal microbiome as a predictor for outcome of in vitro fertilization with or without intracytoplasmic sperm injection: a prospective study. https://app.cochat.ai/papers/10.1093/humrep/dez065
The paper
Koedooder, R., Singer, M., Schoenmakers, S., Savelkoul, P. H. M., Morré, S. A., de Jonge, J. D., Poort, L., Cuypers, W. J. S. S., Beckers, N. G. M., Broekmans, F. J. M., Cohlen, B. J., den Hartog, J. E., Fleischer, K., Lambalk, C. B., Smeenk, J. M. J. S., Budding, A. E., & Laven, J. S. E. (2019). The vaginal microbiome as a predictor for outcome of in vitro fertilization with or without intracytoplasmic sperm injection: a prospective study. Human Reproduction. https://doi.org/10.1093/humrep/dez065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.